Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 2 July 2009, Vol. 114, No. 1, pp. 20-25.
Prepublished online as a Blood First Edition Paper on April 2, 2009; DOI 10.1182/blood-2009-01-199109.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables and Figure
Right arrow All Versions of this Article:
blood-2009-01-199109v1
114/1/20    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Lok, C. Y.
Right arrow Articles by Robson, K. J.H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lok, C. Y.
Right arrow Articles by Robson, K. J.H.
Related Collections
Right arrow Free Research Articles
Right arrow Red Cells, Iron, and Erythropoiesis
Right arrow Clinical Trials and Observations
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

Iron overload in the Asian community

Chun Yu Lok1, Alison T. Merryweather-Clarke1,2, Vip Viprakasit1,3, Yingyong Chinthammitr4, Somdet Srichairatanakool5, Chanin Limwongse3, David Oleesky6, Anthony J. Robins6, John Hudson7, Phyu Wai8, Anuja Premawardhena9, H. Janaka de Silva9, Anuradha Dassanayake10, Carole McKeown11, Maurice Jackson12, Rousseau Gama13,14, Nasaim Khan15, William Newman15, Gurvinder Banait16, Andrew Chilton17, Isaac Wilson-Morkeh17, David J. Weatherall1, and Kathryn J.H. Robson1

1 Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, and 2 Blood Research Laboratory, National Blood Service, John Radcliffe Hospital, Headington, Oxford, United Kingdom; Departments of 3 Paediatrics and 4 Internal Medicine, Siriraj-Thalassemia Research Program and World Health Organization Collaborating Center for the Control of Haemoglobinopathies, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 5 Department of Biochemistry, Faculty of Medicine, Chang Mai University, Chang Mai, Thailand; Departments of 6 Biochemistry, 7 Haematology, and 8 Endocrinology, Macclesfield Hospital, Macclesfield, United Kingdom; Departments of 9 Medicine and 10 Pharmacology, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka; 11 Clinical Genetics, Birmingham Women's Hospital, Birmingham, United Kingdom; 12 Renal Unit and 13 Clinical Chemistry, New Cross Hospital, Wolverhampton, United Kingdom; 14 Research Institute, Healthcare Sciences, Wolverhampton University, Wolverhampton, United Kingdom; 15 Regional Genetic Service and Medical Genetic Research Group, St Mary's Hospital, Central Manchester and Manchester Children's Hospital National Health Service (NHS) Trust, Manchester, United Kingdom; 16 Royal Blackburn Hospital, Blackburn, United Kingdom; and 17 Kettering General Hospital NHS Foundation Trust, Kettering, United Kingdom

Hereditary hemochromatosis is an iron overload disorder that can lead to the impairment of multiple organs and is caused by mutations in one or more different genes. Type 1 hemochromatosis is the most common form of the disease and results from mutations in the HFE gene. Juvenile hemochromatosis (JH) is the most severe form, usually caused by mutations in hemojuvelin (HJV) or hepcidin (HAMP). The autosomal dominant form of the disease, type 4, is due to mutations in the SLC40A1 gene, which encodes for ferroportin (FPN). Hereditary hemochromatosis is commonly found in populations of European origin. By contrast, hemochromatosis in Asia is rare and less well understood and can be masked by the presence of iron deficiency and secondary iron overload from thalassemia. Here, we provide a comprehensive report of hemochromatosis in a group of patients of Asian origin. We have identified novel mutations in HJV, HAMP, and SLC40A1 in countries not normally associated with hereditary hemochromatosis (Pakistan, Bangladesh, Sri Lanka, and Thailand). Our family studies show a high degree of consanguinity, highlighting the increased risk of iron overload in many countries of the developing world and in countries in which there are large immigrant populations from these regions.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Iron overload in Asia
Chaim Hershko
Blood 2009 114: 1-2. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
A. Fernandes, G. C. Preza, Y. Phung, I. De Domenico, J. Kaplan, T. Ganz, and E. Nemeth
The molecular basis of hepcidin-resistant hereditary hemochromatosis
Blood, July 9, 2009; 114(2): 437 - 443.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Hershko
Iron overload in Asia
Blood, July 2, 2009; 114(1): 1 - 2.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020